speaking of IP value boxes, Merck just announced a US$10.8B deal for a discovery platform biotech in phase 2, check out the chart - amazing share price growth pre-deal, which takes the all cash share price to $200 from $114 when it opens for trading today. Just goes to show an example of an inherently undervalued/not understood precision medicine platform sitting on the market in plain sight. Happens in both US / NASDAQ and AU / ASX, so the complexity of assessing value is a market participant problem; who has the IQ or niche experience to assess these IP value from the lens of a big pharma?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)